ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1033

Stat3 Promotes IL-10 Expression in SLE T Cells through Trans-activation and Chromatin Remodeling

Christian Hedrich1, Thomas Rauen2, Sokratis Apostolidis3, Alexandros P. Grammatikos4, Noe Rodriguez Rodriguez4, Christina Ioannidis3, Vasileios C. Kyttaris4, José C. Crispin4 and George C. Tsokos5, 1Children's Hospital, Dresden, Germany, 2Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, 3Medicine, Rheumatology, BIDMC, Boston, MA, 4Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Epigenetics, methylation, systemic lupus erythematosus (SLE) and transcription factor, T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

IL-10 is an immune-regulatory cytokine that is expressed by a wide range of cells and tissues. It plays a central role in the regulation of the innate and adaptive immune system. IL-10 is elevated in the serum and tissues of patients with the autoimmune disorder systemic lupus erythematosus (SLE). SLE is characterized by autoantibody production, immune complex formation, and altered cytokine expression. Because IL-10 exhibits B cell-promoting effects, it has been suggested as a contributor to autoantibody production and tissue damage in SLE. In this study, we aimed to determine molecular events governing T cell-derived IL-10 expression in health and disease.

Methods:

To achieve this, we forced the expression of the transcription factors Stat3 or Stat5, or inhibited them through siRNAs or chemical inhibitors in human T cells. Furthermore, IL10 reporter constructs have been utilized to determine the relative contribution of Stat3/5 on specific regulatory elements in the IL10proximal promoter and an intronic enhancer. The influence of two major epigenetic events, DNA methylation and histone acetylation, on IL-10 expression has been determined using MeDIP or ChIP assays. Furthermore, we determined potential interactions between Stat transcription factors and the transcriptional co-regulator p300, using transfection systems, siRNA and chemical inhibition strategies, and proximity ligation assays.

Results:

We link reduced DNA methylation of IL10 regulatory regions with increased recruitment of Stat transcription factors. IL-10 is regulated by both Stat3 and Stat5 through their differential recruitment to the IL10 promoter (Stat3) and an intronic enhancer (Stat5). Stat3 and Stat5 trans-activate regulatory elements and induce epigenetic remodeling of IL10through their interaction with the histone acetyltransferase p300. Of note, in T cells from SLE patients, activation of Stat3 is increased, resulting in enhanced recruitment to regulatory regions and competitive replacement of Stat5 at the intronic enhancer, subsequently promoting IL-10 expression.

Conclusion:

Understanding the molecular events governing cytokine expression will provide new treatment options in autoimmune disorders, including SLE. The observation that altered Stat3 activation enhances IL-10 expression in T cells offers a potential target in the search for novel biomarkers and treatment options in SLE.


Disclosure:

C. Hedrich,
None;

T. Rauen,
None;

S. Apostolidis,
None;

A. P. Grammatikos,
None;

N. Rodriguez Rodriguez,
None;

C. Ioannidis,
None;

V. C. Kyttaris,
None;

J. C. Crispin,
None;

G. C. Tsokos,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stat3-promotes-il-10-expression-in-sle-t-cells-through-trans-activation-and-chromatin-remodeling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology